United States Liquid Biopsy Market, Size, Forecast 2024-2030, Industry Trends, Growth, Outlook, Insight, Top Companies Analysis
United States Liquid Biopsy Market Outlook
United States Liquid Biopsy Market is expected to reach US$ 803.8 Million by 2027. Liquid biopsy is the molecular examination of nucleic acids, subcellular structures, particularly exosomes, and, in the case of cancer, circulating tumor cells in bodily fluids. Liquid biopsy has been the subject of intense research over the last ten years to develop a less invasive and more precise individualized therapy. Furthermore, due to its sophisticated nature, which includes a short turnaround time and feasibility and the capacity to do early cancer screening, liquid biopsies are becoming more popular in the United States.
United States Liquid Biopsy Market Size is expected to expand at a CAGR of 17.50% during 2021-2027:
The liquid biopsy methods are minimally invasive and cost-effective in the United States. As a result, they are a popular alternative for cancer diagnosis among Americans. Other essential driving factors influencing the US liquid biopsy market in the projected period include an increase in patient demand for non-invasive treatment procedures and the number of cancer patients. However, the reduced sensitivity of some liquid biopsies may limit market growth in the United States throughout the foreseeable period.
How COVID-19 Affected United States Liquid Biopsy Industry:
The coronavirus outbreak damaged the US biopsy diagnostics centers, hospitals, supply chains, and clinical trials. As a result, cancer diagnoses were being delayed since clinics had been closed since the start of the COVID-19 pandemic, and diagnosis and screening services were growing slower. In addition, cancer patients had numerous obstacles outside of the pandemic, including increased susceptibility to severe infection and disruptions in treatment or routine medical care. According to our estimates, the United States Liquid Biopsy Market reached US$ 305.4 Million in 2021 post recovery from the pandemic scenario.
Lung Cancer Accounts for The Dominant Market Share in The Forecast Period:
The liquid biopsy market in the United States is split into four categories: lung cancer, breast cancer, colorectal cancer, and prostate cancer. Lung cancer is expected to have the largest market share during the projection period. According to the American Cancer Society, non-small-cell lung cancer, the most frequent kind of lung cancer in the United States, will be diagnosed in 235,760 persons in 2021. Lung cancer affects one in every 17 men and one in every 15 women at some point in their lives.
By Product, Assay Kits Holds the Largest Market Share:
The liquid biopsy market in the United States is classified into three categories: kits and consumables, instruments, and services. Thekits and consumablesare expected to have the most significant market share during the projection period. In the projection period, demand for kits and consumableswill be driven by the ability to repeat sampling for liquid biopsy and their convenience and affordability.
Circulating Tumor Cells Maintains Their Dominance:
The liquid biopsy market in the United States is classified into Circulating tumor cells (CTCs), Circulating tumor DNA (ctDNA), Extracellular vesicles (EVs), and Other biomarkers based on the circulating biomarker (cell-free DNA, etc.). Circular tumor cells are expected to maintain their dominance throughout the predicted period. The market demand for Circulating tumor DNA is being driven by the rising frequency of cancer and the introduction of ctDNA-based liquid biopsy analysis, which can evaluate prognosis and tumor progression (ctDNA).
Other Segment Covered in Our Report Includes the Following:
- Based on clinical application, the market has been segmented into monitoring, prognosis, theranostics, and screening.
- In addition, the market has been segmented into blood, urine, and others based on a sample.
- Finally, based on application, the market has been segmented into molecular health monitoring, therapy selection for other meta cancer, and therapy selection for MBS.
- The market has been segmented into hospitals and laboratories and government & academic research centers based on end-user.
Key Companies Insights:
Thermo Fisher Scientific Inc, Roche Diagnostics, Bio-Rad Laboratories Inc, Biocept, Inc., Biocartis, Myriad Genetics, Inc., Exact Sciences (Genomic Health), NeoGenomics Laboratories, Quest Diagnostic Inc, and Qiagen are among the important players profiled in our report. These market players in the United States contribute to market growth by diversifying their cancer diagnostics portfolios, resulting in increased demand for their biopsy test kits.
Renub Research latest report “United States Liquid Biopsy Market, Forecast By Cancer (Lung Cancer, Breast Cancer, Colorectal Cancer, Prostate Cancer and Others), By Product (Kits & Consumables, Instruments and Services), Circulating Biomarkers (Circulating tumor cell (CTCs), Circulating tumor DNA (ctDNA), Extracellular vesicles (EVs) and Other biomarkers (cell free DNA,etc)), Clinical Application (Monitoring, Prognosis, Theranostics and Screening), Sample (Blood, Urine and Others), Application (Molecular Health Monitoring, Therapy Selection for Other Meta Cancer and Therapy Selection for MBS), End User (Hospitals and Laboratories and Government & Academic Research Centers), Companies (Thermo Fisher Scientific Inc, Roche Diagnostics, Bio-Rad Laboratories Inc, Biocept, Inc., Biocartis, Myriad Genetics, Inc., Exact Sciences (Genomic Health), NeoGenomics Laboratories, Quest Diagnostic Inc and Qiagen)” provides a detailed analysis of United States Liquid Biopsy Industry.
By Cancer, the Market has been segmented into 5 viewpoints:
1. Lung Cancer
2. Breast Cancer
3. Colorectal Cancer
4. Prostate Cancer
5. Others
By Product the Market has been segmented into 3 viewpoints:
1. Kits & Consumables
2. Instruments
3. Services
By Circulating Biomarkers, the market has been segmented into 4 viewpoints:
1. Circulating tumor cell (CTCs)
2. Circulating tumor DNA (ctDNA)
3. Extracellular vesicles (EVs)
4. Other biomarkers (cell free DNA,etc)
By Clinical Application the market has been segmented into 4 viewpoints:
1. Monitoring
2. Prognosis
3. Theranostics
4. Screening
By Sample the market has been segmented into 3 viewpoints:
1. Blood
2. Urine
3. Others
By Application, the market has been segmented into 3 viewpoints:
1. Molecular Health Monitoring
2. Therapy Selection for Other Meta Cancer
3. Therapy Selection for MBS
By End User, the market has been segmented from 2 viewpoints:
1. Hospitals and Laboratories
2. Government & Academic Research Centers
Company Insights:
• Overview
• Product Portfolio
• Financial Insight
Companies Covered:
1. Thermo Fisher Scientific Inc
2. Roche Diagnostics
3. Bio-Rad Laboratories Inc
4. Biocept, Inc.
5. Biocartis
6. Myriad Genetics, Inc.
7. Exact Sciences (Genomic Health)
8. NeoGenomics Laboratories
9. Quest Diagnostic Inc
10. Qiagen
Report Details:
Report Features | Details |
Base Year | 2021 |
Historical Period | 2016 - 2021 |
Forecast Period | 2022 - 2027 |
Market | US$ Million |
Segment Covered | Cancer, Product, Circulating Biomarkers, Clinical Application, Application & End User |
Cancer Covered | Lung Cancer, Breast Cancer, Colorectal Cancer, Prostate Cancer and Others |
Companies Covered | Thermo Fisher Scientific Inc, Roche Diagnostics, Bio-Rad Laboratories Inc, Biocept, Inc., Biocartis, Myriad Genetics, Inc., Exact Sciences (Genomic Health), NeoGenomics Laboratories, Quest Diagnostic Inc and Qiagen |
Customization Scope | 20% Free Customization |
Post-Sale Analyst Support | 1 Year (52 Weeks) |
Delivery Format | PDF and Excel through Email (We can also provide the editable version of the report in PPT/Word format on request) |
Frequently Asked Questions:
1. How big was United States Liquid Biopsy Market in 2021?
2. What is the United States Liquid Biopsy Market growth rate?
3. Which segment by application accounted for the largest liquid biopsy market share?
4. Who are the key players in the market?
5. What are the factors driving the market?
6. What has been the COVID-19 impact on the market?
1. Introduction
2. Research & Methodology
3. Executive Summary
4. Market Dynamics
4.1 Growth Drivers
4.2 Challenges
5. United States Liquid Biopsy Market
6. Market Share – United States Liquid Biopsy
6.1 By Cancer
6.2 By Product
6.3 By Circulating Biomarkers
6.4 By Clinical Application
6.6 By Application
6.7 By End User
7. Cancer – United States Liquid Biopsy Market
7.1 Lung Cancer
7.2 Breast Cancer
7.3 Colorectal Cancer
7.4 Prostate Cancer
7.6 Others
8. Product – United States Liquid Biopsy Market
8.1 Kits & Consumables
8.2 Instruments
8.3 Services
9. Circulating Biomarkers – United States Liquid Biopsy Market
9.1 Circulating tumor cell (CTCs)
9.2 Circulating tumor DNA (ctDNA)
9.3 Extracellular vesicles (EVs)
9.4 Other biomarkers (cell free DNA,etc)
10. Clinical Application – United States Liquid Biopsy Market
10.1 Monitoring
10.2 Prognosis
10.3 Theranostics
10.4 Screening
11. Sample – United States Liquid Biopsy Market
11.1 Blood
11.2 Urine
11.3 Others
12. Application – United States Liquid Biopsy Market
12.1 Molecular Health Monitoring
12.2 Therapy Selection for Other Meta Cancer
12.3 Therapy Selection for MBS
13. End User – United States Liquid Biopsy Market
13.1 Hospitals and Laboratories
13.2 Government & Academic Research Centers
14. Company Analysis
14.1 Thermo Fisher Scientific Inc
14.1.1 Overview
14.1.2 Product Portfolio
14.1.3 Financial Insight
14.2 Roche Diagnostics
14.2.1 Overview
14.2.2 Product Portfolio
14.2.3 Financial Insight
14.3 Bio-Rad Laboratories Inc
14.3.1 Overview
14.3.2 Product Portfolio
14.3.3 Financial Insight
14.4 Biocept, Inc.
14.4.1 Overview
14.4.2 Product Portfolio
14.4.3 Financial Insight
14.5 Biocartis
14.5.1 Overview
14.5.2 Product Portfolio
14.5.3 Financial Insight
14.6 Myriad Genetics, Inc
14.6.1 Overview
14.6.2 Product Portfolio
14.6.3 Financial Insight
14.7 Exact Sciences (Genomic Health)
14.7.1 Overview
14.7.2 Product Portfolio
14.7.3 Financial Insight
14.8 NeoGenomics Laboratories
14.8.1 Overview
14.8.2 Product Portfolio
14.8.3 Financial Insight
14.9 Quest Diagnostic Inc
14.9.1 Overview
14.9.2 Product Portfolio
14.9.3 Financial Insight
14.10 Qiagen
14.10.1 Overview
14.10.2 Product Portfolio
14.10.3 Financial Insight
List of Figures:
Figure-01: United States – Liquid Biopsy Market (Million US$), 2017 – 2021
Figure-02: United States – Forecast for Liquid Biopsy Market (Million US$), 2022 – 2027
Figure-03: United States – Lung Cancer Market (Million US$), 2017 – 2021
Figure-04: United States – Forecast for Lung Cancer Market (Million US$), 2022 – 2027
Figure-05: United States – Breast Cancer Market (Million US$), 2017 – 2021
Figure-06: United States – Forecast for Breast Cancer Market (Million US$), 2022 – 2027
Figure-07: United States – Colorectal Cancer Market (Million US$), 2017 – 2021
Figure-08: United States – Forecast for Colorectal Cancer Market (Million US$), 2022 – 2027
Figure-09: United States – Prostate Cancer Market (Million US$), 2017 – 2021
Figure-10: United States – Forecast for Prostate Cancer Market (Million US$), 2022 – 2027
Figure-11: United States – Others Market (Million US$), 2017 – 2021
Figure-12: United States – Forecast for Others Market (Million US$), 2022 – 2027
Figure-13: Product – Kits & Consumables Market (Million US$), 2017 – 2021
Figure-14: Product – Forecast for Kits & Consumables Market (Million US$), 2022 – 2027
Figure-15: Product – Instruments Market (Million US$), 2017 – 2021
Figure-16: Product – Forecast for Instruments Market (Million US$), 2022 – 2027
Figure-17: Product – Services Market (Million US$), 2017 – 2021
Figure-18: Product – Forecast for Services Market (Million US$), 2022 – 2027
Figure-19: Circulating Biomarkers – Circulating tumor cell (CTCs) Market (Million US$), 2017 – 2021
Figure-20: Circulating Biomarkers – Forecast for Circulating tumor cell (CTCs) Market (Million US$), 2022 – 2027
Figure-21: Circulating Biomarkers – Circulating tumor DNA (ctDNA) Market (Million US$), 2017 – 2021
Figure-22: Circulating Biomarkers – Forecast for Circulating tumor DNA (ctDNA) Market (Million US$), 2022 – 2027
Figure-23: Circulating Biomarkers – Extracellular vesicles (EVs) Market (Million US$), 2017 – 2021
Figure-24: Circulating Biomarkers – Forecast for Extracellular vesicles (EVs) Market (Million US$), 2022 – 2027
Figure-25: Circulating Biomarkers – Other biomarkers (cell free DNA,etc) Market (Million US$), 2017 – 2021
Figure-26: Circulating Biomarkers – Forecast for Other biomarkers (cell free DNA,etc) Market (Million US$), 2022 – 2027
Figure-27: Clinical Application – Monitoring Market (Million US$), 2017 – 2021
Figure-28: Clinical Application – Forecast for Monitoring Market (Million US$), 2022 – 2027
Figure-29: Clinical Application – Prognosis Market (Million US$), 2017 – 2021
Figure-30: Clinical Application – Forecast for Prognosis Market (Million US$), 2022 – 2027
Figure-31: Clinical Application – Theranostics Market (Million US$), 2017 – 2021
Figure-32: Clinical Application – Forecast for Theranostics Market (Million US$), 2022 – 2027
Figure-33: Clinical Application – Screening Market (Million US$), 2017 – 2021
Figure-34: Clinical Application – Forecast for Screening Market (Million US$), 2022 – 2027
Figure-35: Sample – Blood Market (Million US$), 2017 – 2021
Figure-36: Sample – Forecast for Blood Market (Million US$), 2022 – 2027
Figure-37: Sample – Urine Market (Million US$), 2017 – 2021
Figure-38: Sample – Forecast for Urine Market (Million US$), 2022 – 2027
Figure-39: Sample – Others Market (Million US$), 2017 – 2021
Figure-40: Sample – Forecast for Others Market (Million US$), 2022 – 2027
Figure-41: Application – Molecular Health Monitoring Market (Million US$), 2017 – 2021
Figure-42: Application – Forecast for Molecular Health Monitoring Market (Million US$), 2022 – 2027
Figure-43: Application – Therapy Selection for Other Meta Cancer Market (Million US$), 2017 – 2021
Figure-44: Application – Forecast for Therapy Selection for Other Meta Cancer Market (Million US$), 2022 – 2027
Figure-45: Application – Therapy Selection for MBS Market (Million US$), 2017 – 2021
Figure-46: Application – Forecast for Therapy Selection for MBS Market (Million US$), 2022 – 2027
Figure-47: End User – Hospitals and Laboratories Market (Million US$), 2017 – 2021
Figure-48: End User – Forecast for Hospitals and Laboratories Market (Million US$), 2022 – 2027
Figure-49: End User – Government & Academic Research Centers Market (Million US$), 2017 – 2021
Figure-50: End User – Forecast for Government & Academic Research Centers Market (Million US$), 2022 – 2027
Figure-51: Thermo Fisher Scientific Inc – Global Revenue (Million US$), 2017 – 2021
Figure-52: Thermo Fisher Scientific Inc – Forecast for Global Revenue (Million US$), 2022 – 2027
Figure-53: Roche Diagnostics – Global Revenue (Million US$), 2017 – 2021
Figure-54: Roche Diagnostics – Forecast for Global Revenue (Million US$), 2022 – 2027
Figure-55: Bio-Rad Laboratories Inc – Global Revenue (Million US$), 2017 – 2021
Figure-56: Bio-Rad Laboratories Inc – Forecast for Global Revenue (Million US$), 2022 – 2027
Figure-57: Biocept, Inc. – Global Revenue (Million US$), 2017 – 2021
Figure-58: Biocept, Inc. – Forecast for Global Revenue (Million US$), 2022 – 2027
Figure-59: Biocartis – Global Revenue (Million US$), 2017 – 2021
Figure-60: Biocartis – Forecast for Global Revenue (Million US$), 2022 – 2027
Figure-61: Myriad Genetics, Inc – Global Revenue (Million US$), 2017 – 2021
Figure-62: Myriad Genetics, Inc – Forecast for Global Revenue (Million US$), 2022 – 2027
Figure-63: Exact Sciences (Genomic Health) – Global Revenue (Million US$), 2017 – 2021
Figure-64: Exact Sciences (Genomic Health) – Forecast for Global Revenue (Million US$), 2022 – 2027
Figure-65: NeoGenomics Laboratories – Global Revenue (Million US$), 2017 – 2021
Figure-66: NeoGenomics Laboratories – Forecast for Global Revenue (Million US$), 2022 – 2027
Figure-67: Quest Diagnostic Inc – Global Revenue (Million US$), 2017 – 2021
Figure-68: Quest Diagnostic Inc – Forecast for Global Revenue (Million US$), 2022 – 2027
Figure-69: Qiagen – Global Revenue (Million US$), 2017 – 2021
Figure-70: Qiagen – Forecast for Global Revenue (Million US$), 2022 – 2027
List of Tables:
Table-01: United States – Liquid Biopsy Market Share by Cancer (Percent), 2017 – 2021
Table-02: United States – Forecast for Liquid Biopsy Market Share by Cancer (Percent), 2022 – 2027
Table-03: United States – Liquid Biopsy Market Share by Product (Percent), 2017 – 2021
Table-04: United States – Forecast for Liquid Biopsy Market Share by Product (Percent), 2022 – 2027
Table-05: United States – Liquid Biopsy Market Share by Circulating Biomarkers (Percent), 2017 – 2021
Table-06: United States – Forecast for Liquid Biopsy Market Share by Circulating Biomarkers (Percent), 2022 – 2027
Table-07: United States – Liquid Biopsy Market Share by Clinical Application (Percent), 2017 – 2021
Table-08: United States – Forecast for Liquid Biopsy Market Share by Clinical Application (Percent), 2022 – 2027
Table-09: United States – Liquid Biopsy Market Share by Application (Percent), 2017 – 2021
Table-10: United States – Forecast for Liquid Biopsy Market Share by Application (Percent), 2022 – 2027
Table-11: United States – Liquid Biopsy Market Share by End User (Percent), 2017 – 2021
Table-12: United States – Forecast for Liquid Biopsy Market Share by End User (Percent), 2022 – 2027
Reach out to us
Call us on
USA: +1-678-302-0700
INDIA: +91-120-421-9822
Drop us an email at
info@renub.com